Nanjing Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company specializing in the development of novel cell therapies for oncology and other indications. The company's lead product, Carvykti (ciltacabtagene autoleucel), is a BCMA-directed CAR-T cell therapy developed in collaboration with Janssen for the treatment of multiple myeloma. Legend utilizes its proprietary LCAR platform to design and manufacture innovative chimeric antigen receptor T-cell therapies. Headquartered in Somerset, New Jersey, with significant operations in Nanjing, China, the company is focused on advancing a diverse pipeline of cell therapies targeting both hematologic malignancies and solid tumors. The company achieved a significant milestone by becoming the first Chinese-originated biotech to have a CAR-T therapy approved by the U.S. FDA. Legend continues to expand its manufacturing footprint globally to support the commercialization of its lead asset and the development of its early-stage pipeline.